This publication does not concern the award of a public contract within the meaning of the Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1) is due to the specifications of the announcement form. This and the use of the medium “TED” does not involve any submission under procurement regulations whose validity is not mandatory by law or procurement regulations. It is a framework agreement with an option to join, which relates to various active substances.

The subject of the contract are medicinal products that contain the active ingredient iron carboxymaltose in a parenteral dosage form.

The subject of the contract are medicinal products that contain the active ingredient rivaroxaban in a separate oral dosage form.

The subject of the contract are medicinal products containing the active ingredient rotigotine